MYC and plasma cell myeloma: In line with these observations, our results show that treatment with PIM-Pd decreases the levels of c-Myc and cyclin D2, two well-known regulators of cell cycle [28,29], whose levels have been previously reported to decrease in myeloma cells when cap-dependent translation is selectively inhibited [30].